bioMérieux has had a mixed run, with the share price down over the past year even after a recent rebound, which puts the focus squarely on whether today's valuation lines up with the cash the business is expected to generate. With fresh product news in molecular diagnostics now in the mix, the question is how much of that future cash flow story the current price already reflects.
-
Over the past 12 months the stock has fallen 20.2%, which puts recent price action at odds with the earlier multi year performance and raises the stakes for what the current cash flow outlook can justify.
-
The BIOFIRE SPOTFIRE Vaginitis Panel winning Dual 510(k) Clearance and a CLIA Waiver from the FDA, with commercial launch in the United States planned for early 2027, can shift expectations around the timing and durability of future cash inflows from point of care testing.
-
If you'd rather focus on earnings, this one's for you. See why bioMérieux's 22.7x P/E tells a different valuation story .
The issue now is whether bioMérieux's current share price is adequately supported by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.
If you are weighing bioMérieux through the lens of its cash flows, it can help to compare that picture with other companies screened for 192 high quality undervalued stocks .
Is bioMérieux Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) approach here takes bioMérieux's future free cash flows and discounts them back to today. The model starts from last twelve month free cash flow of about €567.4 million and assumes that cash generation keeps growing in the coming decade, with projected annual free cash flow moving higher by 2030 and then easing into more moderate growth after that.
On these cash flow assumptions, the DCF points to an estimated intrinsic value that is meaningfully above the current share price of €89.20. The BIOFIRE SPOTFIRE Vaginitis Panel clearance and planned 2027 US launch provides some support for the idea of sustained cash generation from point of care testing, yet the market price still trails what these projected cash flows imply. Find out what bioMérieux could be worth using our Discounted Cash Flow (DCF) estimate .
The bioMérieux Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the bioMérieux valuation puzzle leaves off by spelling out what would need to happen with the group's growth, margins and earnings for the stock to be worth materially more or materially less than today's price, and framing each fair value view as a thesis about the business that can be tracked over time rather than a one off snapshot on the Community page.
Community views on bioMérieux are split between those who see more upside left in the cash flow story and those who think most of it is already in the price.
Bull case: 6% undervalued
"Very high growth in SPOTFIRE point of care, including a 110% increase in installed base in 2025 to 6,400 instruments and planned new use cases such as vaginitis and cardiac markers, increases test throughput per site and can lift both revenue and gross margin mix as higher margin consumables scale..."
Discover why this Narrative puts bioMérieux at 6% undervalued .
Bear case: 12% overvalued
"The main thing that has to go right is that BIOFIRE non-respiratory and SPOTFIRE reagent usage, industrial applications growth, and GO•28 margin gains continue to more than offset respiratory panel declines, weaker instruments demand, China pressure, and new tariffs..."
Explore why this Narrative puts bioMérieux at 12% overvalued .
One more bioMérieux check that sits beside the share price chart
Everything here has focused on what bioMérieux might earn, not on the people steering it or how their pay packets line up with your interests. See who runs bioMérieux and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BIM.PA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
